HIV感染并发/合并的特应性皮炎：发病机制与治疗进展

罗 清*
南开大学医学院

摘要


特应性皮炎（atopic dermatitis，AD）为HIV感染常见的并发/合并症之一。在作为HIV感染并发症的情况下，其发病机制主要涉及免疫异常、微生物群紊乱及皮肤屏障功能障碍等。HIV感染者轻度AD的治疗与单纯AD无明显不同，然而由于担心在免疫缺陷状态下使用免疫抑制剂或免疫调节剂造成不良后果，HIV感染者伴发中重度AD的治疗需要更多地探索使用新疗法进行干预，方法主要包括抑制Th2细胞因子-受体-JAK-STAT通路信号传导及改善微生物群等。

关键词


艾滋病病毒感染；特应性皮炎；发病机制；治疗进展

全文:

PDF


参考


[1]中华医学会感染病学分会艾滋病丙型肝炎学组，中国疾病预防控制中心.中国艾滋病诊疗指南（2021年版）[J].协和医学杂志，2022，13（2）：203-226.

[2]中华医学会皮肤性病学分会免疫学组，特应性皮炎协作研究中心.中国特应性皮炎诊疗指南（2020版）[J].中华皮肤科杂志，2020，53（2）：81-88.

[3]Garg T, Sanke S. Inflammatory dermatoses in human immunodeficiency virus[J]. Indian J Sex Transm Dis AIDS. 2017;38(2):113-120.

[4]Syrbe U, Siveke J, Hamann A.Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression?[J].Springer Semin Immunopathol. 1999;21(3):263-285.

[5]Orlova-Fink N, Chowdhury F.Z, Xiaoming S, et al. Preferential susceptibility of Th9 and Th2 CD4 T cells to X4-tropic HIV-1 infection[J]. AIDS. 2017;31:2211.

[6]Gunathilake R, Schmuth M, Scharschmidt TC, et al. Epidermal barrier dysfunction in non-atopic HIV: evidence for an "inside-to-outside" pathogenesis[J].J Invest Dermatol. 2010;130(4):1185-1188.

[7]Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis[J]. Expert Rev Clin Immunol. 2021;17(8):835-852.

[8]Furue M, Yamamura K, Kido-Nakahara M, et al. Emerging role of interleukin-31 and interleukin-31 receptorin pruritus in atopic dermatitis[J]. Allergy. 2018 Jan;73(1):29-36.

[9]Kiehl P, Falkenberg K, Vogelbruch M, et al. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining[J]. Br J Dermatol. 2001;145(5):720-729.

[10]Edslev SM, AgnerT, AndersenPS.SkinMicrobiome inAtopic Dermatitis[J].Acta DermVenereol.2020;100(12):adv00164

[11]Möbus L, Rodriguez E, Harder I, et al. Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis[J]. J Allergy Clin Immunol. 2021;147(5):1959-1965.e2.

[12]Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis[J]. Lancet Infect Dis. 2010;10(4):251-261.

[13]Yu DM, Zhao J, Lee EE, et al. GLUT3 promotes macrophage signaling and function via RAS-mediated endocytosis in atopic dermatitis and wound healing[J]. J Clin Invest. 2023;133(21):e170706.

[14]Novak N, Koch S, Allam JP, et al. Dendritic cells: bridging innate and adaptive immunity in atopic dermatitis[J]. J Allergy Clin Immunol. 2010;125(1):50-59.

[15]Savolainen J, Kosonen J, Kortekangas-Savolainen O, et al. HLA-DR-dependent increased mannan-induced lymphoproliferative response in atopic eczema dermatitis syndrome[J]. Allergy. 2003;58(1):72-77.

[16]曹婷，邹颖.特应性皮炎与皮肤微生态研究进展[J].实用皮肤病学杂志，2020，13（3）.

[17]Su H, Luo Y, Sun J, et al. Transglutaminase 3 Promotes Skin Inflammation in Atopic Dermatitis by Activating Monocyte-Derived Dendritic Cells via DC-SIGN[J]. J Invest Dermatol. 2020;140(2):370-379.e8.

[18]KurniadiI, Hendra Wijaya W, Timotius KH.Malasseziavirulence factors and their role in dermatological disorders[J].Acta Dermatovenerol Alp Pannonica Adriat.2022;31(2):65-70.

[19]Lu W, Feng Y, Jing F, et al. Association Between Gut Microbiota and CD4 Recovery in HIV-1 Infected Patients[J]. Front Microbiol. 2018;9:1451.

[20]JorgensenJ, Bach-MortensenN, KochC, et al.Bacteria and endotoxin induce release of basophil histamine in patients with atopic dermatitis. In vitro experiments with S.aureus, teichoicacid, E.coli and E.coliLPS[J].Allergy.1987;42(5):395-397.

[21]Guttman-Yassky E, Irvine AD, Brunner PM, et al. The role of Janus kinase signaling in the pathology of atopic dermatitis[J].JAllergy Clin Immunol.2023;152(6):1394-1404.

[22]Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment[J]. Am Fam Physician. 2020;101(10):590-598.

[23]GadeA, Ghani H, Patel P, et al. Dupilumab[OL].In:StatPearls.TreasureIsland(FL):StatPearls Publishing; February 28, 2024.

[24]Simpson EL, Schlievert PM, Yoshida T, et al. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment[J]. J Allergy Clin Immunol. 2023;152(5):1179-1195.

[25]Patella V, Florio G, Petraroli A, et al. HIV-1 gp120 induces IL-4 and IL-13 release from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE[J]. J Immunol. 2000;164(2):589-595.

[26]Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors[J]. Allergol Int. 2022;71(1):40-46.


Refbacks

  • 当前没有refback。